Healthcare has the best long-duration demand story in the S&P 500, but the market is finally asking a harder question: who actually captures the economics? The U.S. population aged 65 and older has climbed from roughly 35 million in 2000 to about 58 million in 2022, and Census projections point toward more than 80 million by mid-century. That is a structural volume tailwind for drugs, hospitals, medical devices, diagnostics and managed care. Yet the Inflation Reduction Act has also introduced the most important drug pricing reset in two decades, with Medicare negotiation beginning for selected high-spend therapies and inflation rebates already reshaping launch-price behavior.
For equity investors, this is not a binary bull-bear healthcare call. It is a sector rotation within healthcare. Companies with procedure exposure, durable utilization growth, service scale or patent-protected innovation can still compound cash flow. Companies relying on mature branded drug franchises with Medicare-heavy exposure deserve lower terminal value assumptions. In my coverage framework, the sector has moved from a broad defensive allocation to a dispersion trade built around pricing power, policy insulation and reinvestment efficiency.
Aging Is a Volume Tailwind, Not a Blanket Valuation Argument
The demographic math is straightforward. Older adults consume a disproportionate share of healthcare resources: CMS data consistently show per-capita spending for seniors running several multiples above working-age adults, driven by chronic disease, oncology, cardiovascular care, orthopedic procedures and post-acute services. U.S. national health expenditure was about $4.5 trillion in 2022, or 17.3% of GDP, and the agency’s long-range projections have healthcare spending growing faster than nominal GDP over the next decade.
That volume is especially relevant for medical technology and providers. Hip and knee replacement demand should rise with an older but more active population, supporting Stryker, Zimmer Biomet and Johnson & Johnson’s orthopedics franchise. Structural heart, electrophysiology and robotic surgery address markets that are both underpenetrated and age-correlated, benefiting Boston Scientific, Abbott Laboratories and Intuitive Surgical. Hospitals such as HCA Healthcare and Tenet Healthcare get procedure leverage when staffing costs stabilize, while outpatient surgery centers gain share as payers push care into lower-cost settings.
But demographic demand does not automatically translate into higher equity value. In DCF terms, the question is whether unit growth offsets price pressure, labor inflation and reimbursement risk. A device company growing revenue 6% to 8% organically with 70% gross margins and modest pricing pressure can justify a premium multiple even at a higher discount rate. A hospital with 3% same-facility volume growth but persistent wage inflation and Medicaid exposure deserves a more cautious free cash flow yield. The aging theme is powerful, but the market pays for operating leverage, not just patient counts.
Drug Pricing Reform Changes the Shape of Pharma Cash Flows
The Inflation Reduction Act is the key policy variable. Medicare can negotiate prices for a small but expanding list of high-spend drugs, beginning with the first 10 Part D products selected for 2026 implementation. That list included Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and certain insulin products, representing more than $50 billion of gross Medicare Part D spending over the measurement period cited by CMS. The law also imposes inflation rebates and caps Medicare Part D out-of-pocket costs at $2,000 starting in 2025.
The market impact is subtler than a one-year earnings haircut. Negotiation eligibility begins after 9 years for small molecules and 13 years for biologics, which effectively shortens the high-certainty cash-flow runway for some drug categories. That matters because large-cap pharma valuation is highly sensitive to terminal value. If a mature product’s post-exclusivity erosion starts earlier or becomes more predictable, investors should lower the fade-period margin and revenue assumptions rather than simply haircut next year’s EPS.
The biggest pressure points are companies with concentrated exposure to Medicare-heavy chronic therapies and limited pipeline replacement. Bristol Myers Squibb, Pfizer and parts of Merck’s later-decade portfolio face the classic patent-cliff problem: high current free cash flow but rising uncertainty around reinvestment returns. AbbVie remains a useful case study. Humira erosion was well telegraphed, but the equity multiple depended on whether Skyrizi and Rinvoq could credibly rebuild the growth algorithm. That is the template: the market will reward pharma only when pipeline assets are not just scientifically promising, but commercially large enough to replace negotiated or expiring revenue.
My base case is that drug reform compresses multiples for mature revenue streams, not for genuine innovation. The equity market will pay for clinical differentiation; it will not pay the same multiple for administratively protected pricing.
GLP-1s Are the Exception That Proves the Rule
Eli Lilly and Novo Nordisk have become the clearest examples of how innovation can overpower policy anxiety. GLP-1 therapies for diabetes and obesity address one of the largest metabolic markets in global healthcare, with obesity prevalence above 40% among U.S. adults by CDC estimates. The revenue opportunity spans diabetes, weight management, cardiovascular risk reduction and potentially kidney, liver and sleep apnea indications. Even after capacity constraints and payer scrutiny, the addressable market is large enough to justify capital expenditure programs that would look aggressive in most other subsectors.
For investors, the GLP-1 debate is not whether demand exists; it is whether long-term gross-to-net discounts, Medicare coverage restrictions and competition reduce the extraordinary margin profile. A DCF for Lilly that assumes sustained high-teens revenue growth through the late 2020s can still support a premium valuation, but the terminal multiple becomes vulnerable if obesity treatment shifts from scarcity pricing to payer-managed chronic utilization. In other words, the stocks can be fundamentally attractive and still highly sensitive to small changes in long-run penetration and net price assumptions.
The second-order effects are equally important. If GLP-1 adoption reduces cardiovascular events, joint replacements or dialysis progression over time, parts of medtech and dialysis services may face narrative pressure. I would be careful not to overstate the near-term earnings risk. Orthopedic backlogs, aging joints and surgical innovation remain real. Dialysis demand is tied to complex kidney disease dynamics. But portfolio managers increasingly price healthcare as an ecosystem, and GLP-1 leaders have absorbed a share of the sector’s growth premium that previously might have gone to broader life sciences and devices.
Managed Care: Demographics Help Revenue, Utilization Hurts Margins
Managed care sits at the intersection of aging demographics and policy. Medicare Advantage enrollment has grown to more than half of eligible Medicare beneficiaries, creating a durable top-line channel for UnitedHealth Group, Humana, CVS Health’s Aetna and Elevance. The appeal is scale: larger insurers can manage networks, pharmacy benefit economics, risk coding, data analytics and care coordination more efficiently than smaller plans. UnitedHealth’s Optum franchise remains the benchmark for vertical integration because it captures economics across care delivery, pharmacy services and analytics.
Yet the margin cycle has become more difficult. Older members are using more services after pandemic-era deferrals, Medicare Advantage rate updates have tightened, and risk-adjustment scrutiny has increased. For Humana, which is more concentrated in Medicare Advantage, small shifts in medical cost trends can materially change earnings power. For diversified players, commercial pricing and services revenue provide more ballast. The investment distinction is critical: demographic growth lifts premium revenue, but valuation depends on whether medical loss ratios can normalize.
In a DCF, I would not use the same terminal margin for a pure-play Medicare Advantage book that I would for a diversified healthcare services platform. A 50 to 100 basis point difference in normalized operating margin can move fair value by double digits when applied to a large premium base. That is why the market has rewarded diversified earnings streams and punished plans when utilization data surprise to the upside.
Where Multiples Should Expand, and Where They Should Not
Healthcare has often traded as a defensive sector when rates rise or economic growth slows, but today’s setup is more selective. If the S&P 500 is priced at an elevated forward earnings multiple because of mega-cap technology, healthcare can look relatively inexpensive on a headline basis. The problem is that the sector’s earnings quality varies widely. A low multiple on a patent-cliff pharma company may be a value trap, while a high multiple on a medtech compounder may be justified by visible mid-single-digit procedure growth and improving margins.
The cleanest long-term exposures share four characteristics:
- Low direct IRA exposure: device makers, tools companies and service platforms have less direct risk from Medicare drug negotiation than branded pharma.
- Procedure or utilization growth: orthopedics, electrophysiology, structural heart and robotic surgery benefit directly from aging and underpenetration.
- Balance sheet flexibility: companies with net cash or moderate leverage can acquire innovation while weaker peers sell assets or cut buybacks.
- Pricing tied to value, not habit: therapies with clear survival, hospitalization or productivity benefits are more defensible under payer scrutiny.
Life sciences tools deserve a separate mention. Danaher and Thermo Fisher were de-rated as bioprocessing and biotech funding normalized after the pandemic boom. Their end markets are not immune to budget cycles, but they sell mission-critical equipment and consumables into research, diagnostics and biologics manufacturing. If biotech capital markets reopen and pharma outsourcing stabilizes, these stocks can recover without relying on drug pricing power. The timing is cyclical; the franchise quality is structural.
Portfolio Implications: Barbell the Sector
My preferred healthcare equity strategy is a barbell. On one side, own innovation leaders with demonstrable clinical and commercial scale, even if headline multiples appear demanding. Lilly and Novo Nordisk fit this category, though position sizing should reflect valuation sensitivity. Select medtech names with durable procedure growth, such as Boston Scientific, Intuitive Surgical and Stryker, also belong here because their revenue streams are tied to volume and technology adoption rather than U.S. drug price inflation.
On the other side, own diversified healthcare services with scale advantages, but demand evidence that utilization pressure is priced in. UnitedHealth remains the highest-quality compounder in managed care, yet even quality deserves a margin-of-safety discipline when regulatory headlines rise. I would be more cautious on business models heavily exposed to Medicare Advantage margin resets without offsetting commercial, pharmacy or services earnings.
The underweight bucket is mature pharma where the dividend yield is the primary argument and pipeline replacement remains uncertain. These stocks can rally on cost cuts, buybacks or litigation wins, but the structural multiple is capped if investors see future Medicare negotiation as a recurring revenue tax. A 4% yield is not enough compensation if the base business is shrinking and acquisition-driven growth requires paying up for scarce assets.
The conclusion is that healthcare remains investable, but no longer simple. Aging demographics are a powerful secular demand engine, while drug pricing reform is a structural margin and duration headwind for parts of branded pharma. The winners will be companies that convert demographic volume into free cash flow without depending on legacy U.S. pricing assumptions. For portfolio managers rotating out of crowded technology or seeking recession resilience, healthcare offers real opportunities, but the right question is not whether the sector is defensive. It is which cash flows deserve to be capitalized at a premium in a world where Washington is now part of the valuation model.